VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 560 filers reported holding VALEANT PHARMACEUTICALS INTL in Q1 2015. The put-call ratio across all filers is 2.18 and the average weighting 1.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2017 | $47,000 | -39.7% | 2,695 | -61.9% | 0.01% | -47.6% |
| Q1 2017 | $78,000 | -1.3% | 7,077 | +29.6% | 0.02% | +10.5% |
| Q4 2016 | $79,000 | -21.0% | 5,462 | +33.8% | 0.02% | -24.0% |
| Q3 2016 | $100,000 | +72.4% | 4,082 | +41.9% | 0.02% | +66.7% |
| Q2 2016 | $58,000 | +241.2% | 2,877 | +343.3% | 0.02% | +200.0% |
| Q1 2016 | $17,000 | -69.1% | 649 | +20.4% | 0.01% | -68.8% |
| Q4 2015 | $55,000 | +400.0% | 539 | +618.7% | 0.02% | +700.0% |
| Q4 2014 | $11,000 | +22.2% | 75 | 0.0% | 0.00% | 0.0% |
| Q2 2014 | $9,000 | +28.6% | 75 | +50.0% | 0.00% | +100.0% |
| Q1 2014 | $7,000 | -88.1% | 50 | -90.0% | 0.00% | -87.5% |
| Q4 2013 | $59,000 | +40.5% | 500 | +25.0% | 0.01% | +14.3% |
| Q3 2013 | $42,000 | -10.6% | 400 | -27.3% | 0.01% | -12.5% |
| Q2 2013 | $47,000 | – | 550 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Brave Warrior Advisors | 5,577,892 | $994,984,000 | 31.62% |
| Ruane, Cunniff & Goldfarb | 33,922,192 | $6,051,041,000 | 31.06% |
| LeVasseur Capital Partners LLC | 162,394 | $28,968,000 | 29.76% |
| FARLEY CAPITAL L.P. | 192,130 | $34,272,000 | 27.18% |
| Pershing Square Capital Management | 19,473,933 | $3,473,760,000 | 24.90% |
| Arrow Capital Management, LLC | 109,461 | $19,525,000 | 16.53% |
| Marble Arch Investments | 1,196,900 | $213,503,000 | 16.43% |
| Tesuji Partners | 1,368,040 | $244,414,000 | 15.82% |
| ValueAct Holdings | 14,994,261 | $2,674,676,000 | 15.55% |
| Hound Partners | 3,898,648 | $695,441,000 | 15.04% |